Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12153280 | 1.00 | HTT (0.46) | HTTHPGDKMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL15576813 | 0.89 | HTT (0.48) | HTTHPGDKMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL10127339 | 0.85 | HTT (0.47) | HTTHPGDKMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL22431708 | 0.85 | AGXT (0.41) | HTTHPGDKMT2ASMN1; SMN2GAA | |
| SCHEMBL10112073 | 0.83 | TSHR (0.48) | HTTKMT2ACA1CA2CA9 | |
| SCHEMBL19699720 | 0.83 | TSHR (0.48) | HTTKMT2ACA1CA2CA9 | |
| SCHEMBL12153202 | 0.82 | HTT (0.53) | HTTHPGDKMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL10973793 | 0.75 | HTT (0.57) | HTTHPGDKMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL8607141 | 0.75 | SLC6A2 (0.57) | HTTHPGDKMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL18580919 | 0.75 | SLC6A2 (0.57) | HTTHPGDKMT2ASMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289456-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | SEQUOIA PHARMACEUTICALS, INC., | 2020-09-17 | — | — | US | disclosed |
| US-9849107-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160361287-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9233952-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150284352-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | SEQUOIA PHARMACEUTICALS INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-8673970-B2 | HIV protease inhibitor and cytochrome p450 inhibitor combinations | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20140024671-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS INC (US) | 2014-01-23 | — | — | US | disclosed |
| US-8481520-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120053132-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20110112137-A1 | HIV PROTEASE INHIBITOR AND CYTOCHROME P450 INHIBITOR COMBINATIONS | SEQUOIA PHARMACEUTICALS, INC. (MD) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289456-A1 | METHODS FOR INHIBITING TUMORS AND DRUG RESISTANCE | HCCS, CYP2E1, CYP7A1 | HTT 4552/4885HPGD 236/4885KMT2A 2347/4885 |
| US-20160361287-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | HTT 3140/4885HPGD 140/4885KMT2A 3386/4885 |
| US-20110112137-A1 | HIV PROTEASE INHIBITOR AND CYTOCHROME P450 INHIBITOR COMBINATIONS | SERPINB1, CYP3A43, PREP | HTT 4189/4885HPGD 304/4885KMT2A 2993/4885 |
| US-20140024671-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | HTT 3140/4885HPGD 140/4885KMT2A 3386/4885 |
| US-20120053132-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | HTT 3140/4885HPGD 140/4885KMT2A 3386/4885 |
| US-20150284352-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | CYP2E1, CYP3A43, CYP3A5 | HTT 2132/4885HPGD 147/4885KMT2A 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.